Enzyme could be major player in artery disease

Enzyme could be major player in artery disease
Levels of an enzyme produced when fatty materials build up within the walls of the artery could be as good at predicting heart disease as high blood pressure and bad cholesterol, according to new research published in The Lancet.

The scientists - who were funded by the British Heart Foundation - were looking at an enzyme called Lp-PLA2 and its association with coronary heart disease, stroke and other causes of death.

They found that the enzyme was strongly linked with artery disease but further research would be needed to show conclusively that the enzyme was a cause, rather than an indicator, of disease.

Professor Peter Weissberg, Medical Director at the British Heart Foundation, said:

"This BHF-funded research shows that Lp-PLA2, an enzyme that's produced by inflammatory cells involved in the development of artery disease, appears to play a significant role in the progression of that disease.

"These findings should stimulate research to find drugs that may reduce the levels of Lp-PLA2.

"The acid test will then be to find out if such drugs reduce the risk of heart attacks and strokes in large clinical trials. It will be some time yet before we have the answers."

The BHF funds lots more pioneering, vital and life-saving research, and some of the most important heart health research achievements over the past 45 years have been made thanks to work supported by us

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.